Migraine consists of a constellation of symptoms, one of which is headache.











BY THE AMERICAN HEADACHE SOCIETY®

Disclosures

Purpose/Objective

- 1. Distinguish migraine from other headache types
- 2. Discuss the steps to diagnosing migraine vs other primary headache vs secondary headache
- 3. List FDA-approved and evidence-based acute and preventive migraine therapies
- 4. Discuss proper use and management of migraine therapies
- 5. Identify and debunk common myths about headache

Accreditation Statement

The American Headache Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The American Headache Society designates the live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Claiming CME

- Attend the sessions in full for which credit is sought
- Complete the post-activity evaluation
- A certificate of completion will be available once the evaluation is submitted

Financial Disclosures

The planners and faculty for this activity did not have any relationships to disclose unless listed here/below. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.

Christopher H. Gottschalk, MD, FAHS

Scientific Advisory Board Member - Lundbeck/Alder Biopharmaceuticals, Amgen/Novartis, Biohaven, Axsome, Satsuma, Theranica (July 2019) Speaker's Bureau - Amgen/Novartis, Lilly, Biohaven, Allergan (Ubrelvy), Theranica

Disclosure of Commercial Support

The American Headache Society received funding to support this activity from the following organizations: Eli Lilly and Company

Bibliography

References are included in each presentation/video.





Learning Objectives

- Define migraine
- Discuss how to distinguish migraine from other headache disorders
- Explain acute treatment, migraine prevention, and other management strategies
- Identify common misconceptions about migraine






What is Migraine?





Migraine Definition

An inherited disorder characterized by neurologic, sensory, autonomic, vestibular, cognitive, and gastrointestinal symptoms







Migraine Prevalence

1 billion worldwide



1 in 5 women

1 in 11 children




1 in 16 men

Lancet Neurol. 2018;17:954-976. Neurology. 2007;68:343-9; Curr Pain Headache Rep. 2013;17:341





Migraine Attack Frequency




Cephalalgia. 2011;31:301-15; Headache. 2016 Feb;56(2):306-22.





Phases of a Migraine Attack




Adapted from *Drugs*. 2018;78:411-37.





Pathophysiology of Migraine








New Drug Target in Migraine: CGRP

• Peptide widely expressed in the:

- Central nervous system
- Trigeminovascular system
- Dura
- Released during migraine attacks
- Actions:
 - Vasodilation
 - Inflammation
 - Pain transmission




Goadsby et al. *Physiol Revs* 2017;97:553-622; Edvinsson L et al. *Neurotherapeutics*. 2010;7:164–175.





Who Do Patients Consult for Migraine?




Lipton RB et al. *Headache.* 1998;38:87-96; Gibbs TS et al. *Headache.* 2003;43:330-5; Collins JG.





Headache Remains Underdiagnosed



Lipton RB et al. Headache. 1998;38:87-96.





How Do I Diagnose **Migraine?**





Rule Out Secondary Headache: When to be Concerned

History and Examination



Assess for worrisome signs and symptoms

"SNOOP" Mnemonic

Systemic symptoms (fever, weight loss, myalgias)

Secondary risk factors (HIV, cancer, pregnancy)

Neurologic exam (papilledema, focal deficit, confusion, seizures)

Onset (sudden/thunderclap)

Older (new or progressive headache, especially over 50 years)

Pattern change (new symptoms in previously stable pattern)

Precipitants (Valsalva, position change, sexual activity)

Adapted from Dodick DW. Adv Stud Med. 2003;3:550-555.





Migraine or Tension-type Headache?

	Migraine	Tension-type Headache
Duration	4-72 hours (2-72 in children)	30 minutes – 7 days
Location	Unilateral (40% bilateral)	Bilateral
Description of pain	Pulsating (50% non-pulsating)	Pressing/Tightening (non-pulsating)
Pain intensity	Moderate-severe	Mild-moderate
Effect of routine physical activity	Aggravated by	None
Nausea or vomiting	Yes	No
Photophobia or phonophobia	Both	No more than 1
Attributable	Not attributable to another disorder	Not attributable to another disorder

NOTE: Tension-type headache rarely presents as a chief complaint. If a patient is in your office for complaint of recurring headache, it is likely migraine.

Cephalalgia. 2018;38:1-211.





3-Question Screener: ID Migraine



"PIN" the migraine diagnosis



Photophobia Does light bother you Ha when you have a headache? (≥

mpairmentHas headache limited activity(≥1 day) in the last 3 months?

Nausea

Are you sick to your stomach when you have a headache?

"Yes" to 2 or 3 questions = 93% have migraine

Neurology. 2003;61:375-82.





How Do I Manage **Migraine?**

Acute Treatment

Preventive Treatment

Non-medication Treatments

Manage What Makes Migraine Worse





Acute Treatment

How Do I Manage **Migraine?**





Medications for Acute Treatment

Migraine-specific

- Triptans
- Gepants
- Ditans

NSAIDs

- Ibuprofen
- Naproxen
- Diclofenac

Also consider **Dopamine antagonists**


- Metoclopramide
- Prochlorperazine
- Promethazine

Headache. 2015;55:778-93.





Stratified Care



JAMA. 2000;284(20):2599-605.





Triptan Selection


	Triptan	Formulation(s)	Comments
Patient Name: Jane Doe Address: Date:	Sumatriptan	Oral tablet, nasal spray, nasal powder, SC	Only triptan with subcutaneous option
K Sumatriptan 100 mg tablets	Rizatriptan	Oral tablet*	Shortest T _{max} (1.3 h); use half dose in patients taking propranolol
1 tablet at attack onset, ok to repeat after 2 hours if needed	Eletriptan	Oral tablet	Potent, safest in lactation, preferred in renal impairment
	Naratriptan	Oral tablet	Half-life 6.5 h
John Dolittle MD: Signature:	Zolmitriptan	Oral tablet,* nasal spray	One of two triptans available as nasal spray
	Almotriptan	Oral tablet	Favorable safety and tolerability
	Frovatriptan	Oral tablet	Long half-life (26 h); preferred in menstrual migraine

*Conventional and orally dissolving tablets available





Pearls: Acute Treatment of Migraine



HEADACHE

In Primary Care

first Contact





Acute Treatment

How Do I Manage **Migraine?**






How Do I Manage **Migraine?**

Preventive Treatment





When to Prescribe Preventive Therapy




Neurology. 2000;55:754-62.





Who Is Eligible for Preventive Treatment?




Neurology. 2007;68:343-9





Pearls: Preventive Treatment of Migraine



Can J Neurol Sci. 2012;39(2 Suppl 2):S1-59; Can Fam Physician. 2015;61:670-9; Headache. 2019;59:1-18.

*FDA approved





Common Procedures for Migraine



Nerve blocks

OnabotulinumtoxinA

Trigger point injections

Headache. 2013;53:437-46.; Headache. 2017;57:766-77; Headache. 2014;54:1441-59.





How Do I Manage **Migraine?**

Preventive Treatment





How Do I Manage **Migraine?**

Non-medication Treatments





Neuromodulation Devices Acute and Preventive Treatment

Transcutaneous supraorbital nerve stimulator



Single pulse transcutaneous magnetic stimulator



J Headache Pain. 2020;21:142.





Neuromodulation Devices Acute and Preventive Treatment

Remote electrical neuromodulation*



* Acute treatment only

J Headache Pain. 2020;21:142.



Non-invasive vagus nerve stimulator





Nutraceuticals

Agent	Daily Dose	Notes
Riboflavin (vitamin B2)	400 mg	Urine discoloration
Magnesium	400 mg – 600 mg	Diarrhea; chelated forms better tolerated
Coenzyme Q10	300 mg	Most expensive
Feverfew	50 mg – 300 mg	Low-quality evidence
Melatonin	3 mg	Conflicting evidence

Note: Petasites/Butterbur not currently recommended due to concerns about liver toxicity

Neurology. 2012;78:1346-53; Medicine (Baltimore). 2019;98(3):e14099.; Headache. 2016 Sep;56(8):1257-66.





Behavioral Therapies for Migraine

Supported by data

Have long-lasting benefits

Effective at all life stages

Biofeedback

CBT

Relaxation Training





Endorsed in US Headache Consortium guidelines

• Can be stand alone or combined with other therapies





•

Neurology. 2000;55:754-62.





How Do I Manage **Migraine?**

Non-medication Treatments





How Do I Manage **Migraine?**

Manage What Makes Migraine Worse





Risk Factors for Migraine Progression

Risk Factor	Recommendation
Frequent headaches	Start migraine prevention when appropriate
Overuse of pain relievers	Start migraine prevention, recommend limiting use of acute pain relievers; avoid opioids and barbiturates
Depression	Screen for and treat depression
Other (non-headache) sources of pain	Identify and treat other pain conditions
Asthma	Screen for and treat asthma
Obesity	Consider topiramate, referral to nutrition, increase exercise

Headache. 2019;59(3):306-38.






Answers to Frequently Asked Questions





When is imaging warranted?



Imaging in Headache Disorders



Don't perform neuroimaging studies in patients with **stable headaches** that meet criteria for **migraine**

Don't perform **CT imaging** for headache when **MRI is available**, <u>except</u> in **emergency settings** (eg, acute bleed)



There is **no necessity** to do neuroimaging in patients with **headaches consistent with migraine** with a **normal neurologic examination** and **no atypical features or red flags**




Appropriateness Criteria[®] Headache — good resource for image selection in **specific clinical scenarios**





Do I need to worry about cardiovascular disease with triptans?



Triptans and Cardiovascular Safety


- Most of the data on triptans are derived from patients without known coronary artery disease
- Chest symptoms occurring during use of triptans generally not:
 - Serious
 - Explained by ischemia
- Incidence of serious cardiovascular events with triptans is extremely low in:
 - Clinical trials
 - Clinical practice
- The cardiovascular risk-benefit profile of triptans favors their use in the absence of contraindications, such as:
 - Coronary artery disease
 - History of stroke
 - Peripheral vascular disease
 - Uncontrolled hypertension



Headache. 2004;44(5):414-25.



Migraine: What do I tell patients about stroke risk?



Migraine and Stroke Risk

- Ischemic stroke and migraine with aura strongly associated with:
 - Female sex
 - Young age
 - Use of oral contraceptives
 - Smoking
- People with migraine are more likely to have asymptomatic structural brain lesions
- There is no direct evidence that migraine prevention reduces stroke risk

J Neurol Neurosurg Psychiatry. 2020 Mar 26. pii: jnnp-2018-318254.





Migraine Myth Busters





Migraine Myth Busters

- <u>Myth 1:</u> Migraine = severe headache
- <u>Myth 2: Migraine pain is due to vasodilation</u>
- <u>Myth 3: Migraine headache must always be</u> throbbing
- <u>Myth 4:</u> You can't diagnose migraine without the presence of aura





Migraine Myth Busters

- <u>Myth 5:</u> Sinusitis is a common cause of headache
- <u>Myth 6:</u> Neck pain is rarely a symptom of migraine
- Myth 7: Triptans should be avoided in patients with aura
- Myth 8: Never prescribe triptans with SSRIs/SNRIs








- Make the diagnosis
- Rule out secondary headaches
- Provide acute treatment
- Consider prevention





Online Resource Library



www.americanheadachesociety.org/primarycare







Please share your feedback

https://www.surveymonkey.com/r/FirstContactNonCME



Scan for immediate access



